Comparative review demonstrates pharmacokinetic and clinical differences among triptans in migraine patients, highlighting key factors for individualized therapy.
Key Points
To synthesize and compare the pharmacokinetics, administration routes, and clinical characteristics of various triptan medications used for acute migraine treatment.
Evaluated pharmacological parameters and receptor selectivity across available triptan agents.
Compared routes of administration, time to onset of action, elimination half-life, and dosing considerations.
Triptans exhibit distinct pharmacokinetic profiles, showing substantial variation in bioavailability, half-life, and onset of action.
Formulation diversity, including oral tablets, orally disintegrating tablets, nasal sprays, and subcutaneous injections, addresses variable patient needs such as rapid onset and migraine-associated nausea.